Years of IL-17 vs. IL-23 debate in PsA finally got tested head-to-head: bimekizumab outperformed risankizumab on joint outcomes in the BE BOLD trial, while a GLP-1 combination study suggests weight and metabolic status are active drivers of PsA — not just comorbidities. This recap also digs into early signals that biologic choice may influence whether psoriasis progresses to PsA, and why some well-controlled patients are still in pain.
It’s time for Rheumatology RoundUp from EULAR 2026 from London, UK. Drs. Artie Kavanaugh and Jack Cush review their choice presentations from the meeting, offering their perspectives on impact and applicability.
Md Yuzaiful Md Yusof Yuz6Yusof
2 months ago
#EULAR2026 LB0001 BOLD results in #PsA. First H2H RCT showing superiority of Bimekizumab (IL17A- & F-i) vs Risankizumab (IL-23-i) in primary endpoint, ACR50 49% vs 38% at WK16. The difference was seen from WK4 & sustained to WK24. May help inform choice of Tx @RheumNow #EULARBest https://t.co/s4zbFiepuP
Antoni Chan MD (Prof) synovialjoints
2 months ago
ACR50 at Week 4 was 19.9% (BKZ) vs 7.2% (RZB) nominal p<0.0001. Faster onset, higher sustained joint response. DAPSA LDA/remission 65% vs 55%. Dual IL-17A/F blockade outperforms IL-23 inhibition for joints in #PsA. Abstr LB0001 @RheumNow #EULAR2026 https://t.co/s4z8r1rKte
Jiha Lee JihaRheum
2 months ago
First head-to-head trial to show #PsA joint outcome superiority
BE BOLD: Bimekizumab (BKZ; IL-17A/F dual blockade) beat Risankizumab (RZB: IL-23i) on ACR50 at wk 16 (49.1% vs 38.4%, p=0.0078). BKZ also faster: ACR50 at wk 4 already 19.9% vs 7.2%.
@RheumNow #EULAR2026 LB0001 https://t.co/YMQCpom5xD
Antoni Chan MD (Prof) synovialjoints
2 months ago
Double targeted therapy in refractory SpA/PsA.
76 patients, 17 Spanish centres, up to 6 years follow-up. Median 4 prior biologics.
Remission achieved in 55.6% during follow-up. 28.6% in remission at final visit.
ASDAS improved significantly from 3 months, sustained to 5 https://t.co/g1IPstYYuX
Nelly ZIADE 🍀 Nellziade
2 months ago
🧬 Does spine vs knee enthesis differ immunologically?
Translational scRNAseq study: YES!
Spine produces more IL-23 but shows attenuated IL-17 response vs knee
#POS0084 #EULAR2026 @RheumNow https://t.co/itFrLEXSzZ
Nelly ZIADE 🍀 Nellziade
2 months ago
🧲 Does GUS+GOL combo beat GUS alone on MRI in PsA?
YES for joints - AFFINITY Phase 2a RCT: greater MRI inflammation reduction in 91pts
#OP0186 #EULAR2026 @RheumNow https://t.co/9eIS6lh7WN
Antoni Chan MD (Prof) synovialjoints
2 months ago
Biopsy-guided treatment in PsA: match the drug to the tissue pathotype with 68% in LDA/remission vs 48% standard of care at 6 months. In myeloid CD117+ patients, mean DAPSA reduction at 6 months: IL-17i: −13.5, IL-23i: −12.8, TNFi: −7.5. Synovial biopsy with myeloid CD117+
Aurelie Najm AurelieRheumo
2 months ago
Can we intercept PsA?
Retro study 394 PSO pts 17 yrs follow-up 86 PsA
TNFi linked to higher PsA incidence vs IL- MoA
TNFi 45% vs IL-17i 14% vs IL-23i 10% vs IL-12/23i 11%
After adjustment IL-17i HR 0.35 IL-23i HR 0.17
Needs prospective confirmation!
#OP072 #EULAR2026 https://t.co/88RaukjLjY
